23andMe, working in collaboration with the Milken Institute and Lundbeck, today announced that they have commenced enrollment for a first-of-its kind genetic study designed to gain understanding of the underlying biology of major depressive and bipolar disorders. This study will combine cognitive assessments with genetic data and survey responses to assess how genes influence brain processes – such as attention, decision-making and visual perception – in individuals who live with these serious mental health conditions.
“We know genetics play a role in the development of depression and bipolar, however there is a long pathway from our genes to the manifestation of complex diseases like these,” said Emily Drabant Conley, PhD., Vice President of Business Development at 23andMe. “We need to look at these conditions in a more comprehensive way to advance our understanding. By studying cognitive function alongside genetics and other environmental variables on a massive scale, we hope to take a significant step forward in the study of depression and bipolar.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8150951-23andme-genetic-study-depression-bipolar-disorders/
An international team of researchers led by Gerard D. Schellenberg, PhD, a member of the CurePSP Genetics Consortium and professor of Pathology and Laboratory Medicine in the Perelman School of Medicine at the University of Pennsylvania, has identified three new genes that can increase the risk of people developing Progressive Supranuclear Palsy (PSP).
PSP is a rare neurodegenerative brain disease, similar to Parkinson’s disease, which causes severe disability by destroying parts of cells that allow the brain to function normally. While PSP has underlying biological similarities to Alzheimer’s disease, a disease which primarily affects memory, PSP impacts a person’s physical movement and bodily functions. PSP leads to progressive decline in patients — there is no known cause or cure.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/psp/49958/
The bold and thrilling quest to finally understand the brain—and along with it our mental afflictions, from depression to autism—by a rising star in neuroscience
Sebastian Seung, a dynamic young professor at MIT, is at the forefront of a revolution in neuroscience. He believes that our identity lies not in our genes, but in the connections between our brain cells—our own particular wiring. Seung and a dedicated group of researchers are leading the effort to map these connections, neuron by neuron, synapse by synapse. It is a monumental effort—the scientific equivalent of climbing Mount Everest—but if they succeed, they will uncover the basis of personality, identity, intelligence, memory, and perhaps disorders such as autism and schizophrenia. Seung explains how this new map of a human “connectome” might even enable us to “upload” our brains into a computer, making us effectively immortal.
Connectome is a mind-bending adventure story, told with great passion and authority. It presents a daring scientific and technological vision for at last understanding what makes us who we are, both as individuals and as a species. Find out more here, http://bit.ly/yEBoyq Non-Fiction
Lancôme is unveiling Genes Day on October 22, a one day fundraiser in support of St. Jude Children’s Research Hospital.
In celebration of the beauty of scientific research, Lancôme will donate $7 from each bottle of their latest skin care breakthrough, Génifique Youth Activating Concentrate, sold that day to St. Jude Children’s Research Hospital to support the research and treatment at St. Jude.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/lancome/46646/
An unprecedented Veterans Affairs (VA) research program that promises to advance the sophisticated science of genomics goes national today. “The Veterans Affairs Research and Development Program has launched the Million Veteran Program, or MVP—an important partnership between VA and Veterans to learn more about how genes affect health, and thus, transform health care for Veterans and for all Americans,” announced VA Under Secretary for Health Robert A. Petzel, MD.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/va/48429/
On October 21st, 2011, Lancôme invites customers to experience the “Beauty of Giving” by celebrating Genes Day, a one-day national event Lancôme began in 2010 to support St. Jude Children’s Research Hospital, one of the world’s premier centers for the research and treatment of pediatric cancer and other catastrophic childhood diseases. On this day, Lancôme will donate $7 from the sale of every bottle of Génifique Youth Activating Concentrate to St. Jude. (This is in addition to special promotions and events nationwide surrounding Genes Day throughout the month of October.)
To view Multimedia News Release, go to http://www.multivu.com/mnr/52300-lancome-genes-day-2011-st-jude-julia-roberts-genifique-beauty-of-giving
Released today, The Aging Myth is an explosive new book by noted scientist and anti-aging researcher Joseph Chang, Ph.D., that reveals how new genetic discoveries are challenging traditional anti-aging philosophies and helping people live younger longer. In The Aging Myth, Dr. Chang uses a conversational and accessible style to dispel common myths about aging and explains some of the latest groundbreaking research in the field.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/nuskin/50881/
Weight loss is perhaps the most common New Year’s resolution made and likely the most difficult to keep. Amway North America offers the NUTRILITE® Weight Management Program, which includes a genetic test that helps individuals find their genotype-matched diet, and offers weight management plans matched to that gene test’s results.
To view Multimedia News Release, go to http://www.multivu.com/mnr/53285-amway-nutrilite-weight-management-program-new-year-resolutions-julie-upton
A pill designed to zero in on abnormal genes that drive specific cancers has produced encouraging early results in children with an uncommon but aggressive type of lymphoma, as well as in children with a rare form of neuroblastoma.
A phase 1 clinical trial of the drug crizotinib achieved remissions, with minimal side effects, for 10 of the children participating in a clinical study carried out by the multicenter Children’s Oncology Group (COG). The results were “an exciting proof-of-principle” for the targeted treatment, said the study leader, Yaël P. Mossé, M.D., a pediatric oncologist at The Children’s Hospital of Philadelphia.
“We are entering a new era of cancer therapy, in which we use knowledge of basic biology to design very specific drugs that target cancer cells with potentially less side effects on healthy tissue,” said Mossé. “In addition, as we concentrate on targets in molecular pathways, we move away from an exclusive focus on one form of cancer to customizing treatments according to biological activity. Abnormal ALK activity occurs in subtypes of neuroblastoma and subtypes of lymphoma, so identifying ALK activity in individual patients may enable us to provide the most effective care.”
To view Multimedia News Release, go to http://www.multivu.com/mnr/50776-childrens-hospital-philadelphia-lymphoma-neuroblastoma-oncology-gene-trial
Researchers studying the genetic roots of the most common malignant childhood brain tumor have discovered missteps in three of the four subtypes of the cancer that involve genes already targeted for drug development.
Lluvia de sangre, imágenes que lloran, personas que manifiestan los estigmas de Jesús en su cuerpo… la profunda devoción popular encuentra una explicación a estos hechos: son milagros que expresan un mensaje divino. Pero, ¿qué pasa si estos acontecimientos se examinan científicamente? En su nueva producción original, Discovery en Español viaja por distintos países de América Latina y analiza 16 eventos reales en busca de la verdad. MISTERIOS DE LA FE se transmitirá los jueves a las 9PM E/P, a partir del 13 de junio.
Para más, visite http://www.multivu.com/mnr/61953-discovery-en-espanol-investigative-series-misterios-de-la-fe-june-13
Barrister, peer and Vice-President of the Patients Association Baroness Helena Kennedy has joined a panel of internationally recognised experts for the 3rd Astellas Innovation Debate: i-Genes – What the DNA and Data Revolutions mean for our Health, taking place on Thursday 29th January 2015 at the Royal Institution of Great Britain.
Organised and funded by Astellas, a progressive pharmaceutical company that explores the frontiers of scientific discovery to translate new knowledge into innovative, reliable medicines, the Astellas Innovation Debates are a series of annual events that bring together some of the world’s most progressive thinkers to discuss the role of innovation in solving some of the greatest challenges of our time.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7424051-helena-kennedy-astellas-debate/
